Paper Details

  1. Home
  2. Paper Details

Population Pharmacokinetics of Brigatinib in Healthy Volunteers and Patients With Cancer.

Author: GuptaNeeraj, HanleyMichael J, KersteinDavid, NarasimhanNarayana, OffmanElliot, ProhnMarita, VenkatakrishnanKarthik, WangXiaohui

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study presents a population pharmacokinetic model-based analysis for brigatinib, an oral tyrosine kinase inhibitor approved for the treatment of anaplastic lymphoma kinase-positive metastatic non-small cell lung cancer.
Paper Details　
Original Abstract of the Article :
Brigatinib is an oral tyrosine kinase inhibitor approved in multiple countries for the treatment of patients with anaplastic lymphoma kinase-positive metastatic non-small cell lung cancer who have progressed on or are intolerant to crizotinib. We report a population pharmacokinetic model-based analy...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7862202/

データ提供：米国国立医学図書館（NLM）

Population Pharmacokinetics of Brigatinib in Healthy Volunteers and Patients With Cancer

This research delves into the complex world of pharmacokinetics, studying how drugs are absorbed, distributed, metabolized, and eliminated by the body. Imagine a camel caravan navigating a vast desert, with each camel carrying a unique load and reacting differently to the journey. This research focuses on understanding how a drug, brigatinib, behaves in the body, particularly in patients with cancer.

Tailoring treatment for individual patients

This research highlights the importance of understanding how drugs interact with the body, especially when treating cancer. Just as a skilled caravan leader knows to adjust the pace and route according to the camels' needs, researchers are working to develop personalized treatment strategies based on how drugs are processed by each individual. This study explores the pharmacokinetic profile of brigatinib, a drug used to treat anaplastic lymphoma kinase-positive metastatic non-small cell lung cancer.

Optimizing drug efficacy and safety

This research underscores the significance of understanding drug pharmacokinetics for effective cancer treatment. Imagine a camel caravan reaching its destination safely and efficiently, with each camel carrying its load optimally. This study suggests that by analyzing the pharmacokinetic profile of brigatinib, healthcare professionals can optimize treatment strategies, maximizing drug efficacy and minimizing potential side effects.

Dr.Camel's Conclusion

This research sheds light on the importance of population pharmacokinetics in developing effective cancer treatments. Just as a caravan leader navigates a diverse desert landscape, researchers are working to understand how drugs behave in different individuals, paving the way for more personalized and effective therapies.
Date :
  1. Date Completed 2021-09-30
  2. Date Revised 2021-09-30
Further Info :

Pubmed ID

32816246

DOI: Digital Object Identifier

PMC7862202

Related Literature

Article Analysis
・Effects of brigatinib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.